In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Apellis Pharmaceuticals (NASDAQ:APLS) and its primary competitors in the Biotechnology industry. By closely examining key financial metrics, market position, and growth prospects, our aim is to provide valuable insights for investors and shed light on company’s performance within the industry.
Apellis Pharmaceuticals Background
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | 224.42 | 13.95 | 5.23 | -15.29% | $-0.05 | $0.17 | -5.94% |
| Alkermes PLC | 24.51 | 3.21 | 4.01 | 2.78% | $0.08 | $0.34 | -10.57% |
| TG Therapeutics Inc | 12.12 | 8.27 | 8.79 | 3.67% | $0.05 | $0.15 | 78.0% |
| ACADIA Pharmaceuticals Inc | 9.71 | 3.10 | 3.54 | 25.51% | $0.02 | $0.26 | 9.39% |
| Kiniksa Pharmaceuticals International PLC | 64.17 | 6.49 | 5.61 | 2.57% | $0.02 | $0.11 | 64.95% |
| Average | 27.63 | 5.27 | 5.49 | 8.63% | $0.04 | $0.21 | 35.44% |
This post was originally published here
